182 related articles for article (PubMed ID: 35422802)
1. A Risk Model Developed Based on Necroptosis Predicts Overall Survival for Hepatocellular Carcinoma and Identification of Possible Therapeutic Drugs.
Li Z; Fang J; Chen S; Liu H; Zhou J; Huang J; Liu S; Peng Y
Front Immunol; 2022; 13():870264. PubMed ID: 35422802
[TBL] [Abstract][Full Text] [Related]
2. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
3. A multi-omics-based investigation of the immunological and prognostic impact of necroptosis-related genes in patients with hepatocellular carcinoma.
Yang H; Jiang Q
J Clin Lab Anal; 2022 Apr; 36(4):e24346. PubMed ID: 35293027
[TBL] [Abstract][Full Text] [Related]
4. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
[TBL] [Abstract][Full Text] [Related]
5. m
Qu X; Zhang L; Li S; Li T; Zhao X; Wang N; Shi Y
Oxid Med Cell Longev; 2022; 2022():8301888. PubMed ID: 36246403
[TBL] [Abstract][Full Text] [Related]
6. A necroptosis-related gene signature to predict prognosis and immune features in hepatocellular carcinoma.
Zhang K; Li J; Yuan E
BMC Cancer; 2023 Jul; 23(1):660. PubMed ID: 37452311
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
[TBL] [Abstract][Full Text] [Related]
8. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
9. Identification and analysis of necroptosis-associated signatures for prognostic and immune microenvironment evaluation in hepatocellular carcinoma.
Lu J; Yu C; Bao Q; Zhang X; Wang J
Front Immunol; 2022; 13():973649. PubMed ID: 36081504
[TBL] [Abstract][Full Text] [Related]
10. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
11. Integrated Analysis of Necroptosis-Related Genes for Prognosis, Immune Microenvironment Infiltration, and Drug Sensitivity in Colon Cancer.
He R; Zhang M; He L; Huang J; Man C; Wang X; Lang Y; Fan Y
Front Med (Lausanne); 2022; 9():845271. PubMed ID: 35479956
[TBL] [Abstract][Full Text] [Related]
12. A 4-gene prognostic signature predicting survival in hepatocellular carcinoma.
Chen PF; Li QH; Zeng LR; Yang XY; Peng PL; He JH; Fan B
J Cell Biochem; 2019 Jun; 120(6):9117-9124. PubMed ID: 30582205
[TBL] [Abstract][Full Text] [Related]
13. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
14. Prognosis and Therapeutic Efficacy Prediction of Adrenocortical Carcinoma Based on a Necroptosis-Associated Gene Signature.
Ji D; Zhong R; Fan S
Biomed Res Int; 2022; 2022():8740408. PubMed ID: 35647181
[TBL] [Abstract][Full Text] [Related]
15. Two novel prognostic models for ovarian cancer respectively based on ferroptosis and necroptosis.
Li Y; Gong X; Hu T; Chen Y
BMC Cancer; 2022 Jan; 22(1):74. PubMed ID: 35039008
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of novel signature associated with hepatocellular carcinoma prognosis using Single-cell and WGCNA analysis.
Song H; Ge Y; Xu J; Shen R; Zhang PC; Wang GQ; Liu B
Int J Med Sci; 2023; 20(7):870-887. PubMed ID: 37324188
[No Abstract] [Full Text] [Related]
18. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.
Xu J; Shen X; Zhang B; Su R; Cui M; Yan L; Cao Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34386813
[TBL] [Abstract][Full Text] [Related]
19. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
[TBL] [Abstract][Full Text] [Related]
20. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
